Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.

Investigational new drugs - 1 Apr 2025

Yang Peiyuan, Li Yongchao

Abstract excerpt

Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgical radical treatment, postoperative adjuvant chemotherapy, targeted therapy, and immunotherapy are performed based on pathological staging and immunohistochemistry. Even with these measures, the 5-year survival rate of colorectal cancer is only 65%, and a considerable number of patients still...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colorectal Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 39956882
DOI: 10.1007/s10637-025-01514-x

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.PMID 39956882Read ↗

Targeting KRASG12C in colorectal cancer: the beginning of a new era.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Assessment of KRASG12C inhibitors for colorectal cancerSemantic proximity Read ↗

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal CancerSemantic proximity Read ↗

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.Semantic proximity Read ↗

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancerSemantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.